AI Analyst Summary
Pfizer's primary bull thesis rests on a sharp earnings recovery implied by its forward P/E of 9.8x — a deep discount to the sector — suggesting the market is pricing in significant profit normalization from post-COVID headwinds that analysts expect to reverse. The company has beaten EPS estimates in each of the last 4 quarters, pointing to improving operational discipline even as revenue growth remains a modest 2.6% YoY. The key risk is pipeline execution: if late-stage assets and recent acquisitions fail to drive top-line acceleration, the earnings recovery embedded in the forward multiple may not materialize.
Fundamentals
Pe
Trailing P/E: 35.7x | Forward P/E: 9.8x · 3.0/5
The trailing P/E of 35.7x looks elevated for a large-cap pharma, but the forward P/E of 9.8x is well below the sector median, suggesting near-term earnings recovery. The gap between trailing and forward implies a significant earnings inflection is expected — warranting a neutral-to-constructive score pending delivery.
Peg
PEG Ratio: 2.59x · 2.0/5
A PEG of 2.59 indicates the stock is not cheaply priced relative to its growth expectations. This sits in the above-average concern range, with earnings growth not yet fully justifying the growth premium embedded in the multiple.
Analyst Rating
Hold / Buy consensus (2.5) · 3.0/5
Consensus of 2.5 from 26 analysts (10 Buy / 16 Hold / 2 Sell) sits exactly at the boundary of Hold and Buy. Broad analyst coverage is constructive, but the weight of Hold ratings limits conviction. Capped at 3 given the balanced split.
Earnings Trend
Earnings Growth YoY: N/A | Revenue Growth YoY: 2.6% · 2.0/5
YoY earnings growth is not available, reflecting post-COVID revenue normalization pressures. Revenue growth of 2.6% is modest and below typical sector growth leaders. The absence of measurable earnings growth is a meaningful headwind, though the low forward P/E implies a potential recovery trajectory.
Price Target Beat
EPS Beat Rate: 4 of 4 quarters · 4.0/5
Pfizer has beaten EPS estimates in each of the last 4 reported quarters, demonstrating solid near-term execution. While only 4 quarters of data are available (limiting a full 8-quarter assessment), consistent beats signal disciplined cost management and improving operational delivery.
Management
Consistent EPS beats with modest revenue growth · 3.0/5
Management earns a neutral score. The 4-for-4 EPS beat streak is encouraging and reflects cost discipline, but revenue growth of 2.6% and the absence of clear earnings growth momentum suggest the strategic pivot post-COVID (acquisitions, pipeline investment) has yet to meaningfully bear fruit. Analyst confidence is mixed, consistent with a transitional period.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.